Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye

Experimental Eye Research

Volumn 84, Issue 5, 2007, Pages 922-933

  Wang, F E ^a   Shi, G ^a   Niesman, M R ^b   Rewolinski, D A ^b   Miller, S S ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

adeno associated viral vector; age related macular degeneration; anti angiogenesis; choroidal neovascularization; combination therapy; gene transfer; PDGF; receptor tyrosine kinase; VEGF

Indexed keywords

AG 013711; AG 013764; PARVOVIRUS VECTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; DEPENDOVIRUS; ENZYME INHIBITORS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; IMMUNOENZYME TECHNIQUES; PIGMENT EPITHELIUM OF EYE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247097979     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2007.01.022     Document Type: Article

References (59)

1. Amorapanth P., LeDoux J.E., and Nader K. Different lateral amygdala outputs mediate reactions and actions elicited by a fear-arousing stimulus. Nat. Neurosci. 3 (2000) 74-79
2. Archer D.B., and Gardiner T.A. Electron microscopic features of experimental choroidal neovascularization. Am. J. Ophthalmol. 91 (1981) 433-457
3. Augustin A.J., D'Amico D.J., Mieler W.F., Schneebaum C., and Beasley C. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 243 (2005) 9-12
4. Avery R.L., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., and Giust M.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372 e365
5. Baffi J., Byrnes G., Chan C.C., and Csaky K.G. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 41 (2000) 3582-3589
6. Barouch F.C., and Miller J.W. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration. Int. Ophthalmol. Clin. 44 (2004) 23-32
7. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111 (2003) 1287-1295
8. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev. 15 (2004) 215-228
9. Bird A.C. The Bowman lecture. Towards an understanding of age-related macular disease. Eye 17 (2003) 457-466
10. Brown D.M., Shapiro H., and Schneider S. Subgroup analysis of first-year results of ANCHOR: a phase III, double-masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 47 (2006) S2963
11. Congdon N., O'Colmain B., Klaver C.C., Klein R., Munoz B., Friedman D.S., Kempen J., Taylor H.R., and Mitchell P. Causes and prevalence of visual impairment among adults in the. United States. Arch. Ophthalmol. 122 (2004) 477-485
12. Dejneka N.S., Kuroki A.M., Fosnot J., Tang W., Tolentino M.J., and Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol. Vis. 10 (2004) 964-972
13. Edelman J.L., and Castro M.R. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp. Eye Res. 71 (2000) 523-533
14. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22 (2002) 143-152
15. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110 (2003) 979-986
16. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280 (2001) C1358-C1366
17. Ferris III F.L. A new treatment for ocular neovascularization. N. Engl. J. Med. 351 (2004) 2863-2865
18. Ferris III F.L., Fine S.L., and Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 102 (1984) 1640-1642
19. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
20. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., and Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351 (2004) 2805-2816
21. Green E.S., Rendahl K.G., Zhou S., Ladner M., Coyne M., Srivastava R., Manning W.C., and Flannery J.G. Two animal models of retinal degeneration are rescued by recombinant adeno-associated virus-mediated production of FGF-5 and FGF-18. Mol. Ther. 3 (2001) 507-515
22. Green W.R. Histopathology of age-related macular degeneration. Mol. Vis. 5 (1999) 27
23. Grossniklaus H.E., and Green W.R. Choroidal neovascularization. Am. J. Ophthalmol. 137 (2004) 496-503
24. Hangai M., Moon Y.S., Kitaya N., Chan C.K., Wu D.Y., Peters K.G., Ryan S.J., and Hinton D.R. Systemically expressed soluble Tie2 inhibits intraocular neovascularization. Hum. Gene Ther. 12 (2001) 1311-1321
25. Heier J.S., Shapiro H., and Singh A.A. Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration: two-year efficacy results of the MARINA Study. Invest. Ophthalmol. Vis. Sci. 47 (2006) S2959
26. Hoyng C.B., Vingerling J.R., Hooymans J.M.M., Klamerus K.J., Younis H., Khalil D., Scassellati-Sforzolini B., Russell S., and Schlingemann R.O. AG-013958 (VEGFR inhibitor) achieves effective choroidal concentrations with minimal systemic effects in cynomolgus monkeys and humans with age-related macular disease. Invest. Ophthalmol. Vis. Sci. 46 (2005) 2365
27. Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., Baluk P., Hu-Lowe D.D., Shalinsky D.R., Thurston G., Yancopoulos G.D., and McDonald D.M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165 (2004) 35-52
28. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 9 (2003) 685-693
29. Jo N., Mailhos C., Ju M., Cheung E., Bradley J., Nishijima K., Robinson G.S., Adamis A.P., and Shima D.T. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am. J. Pathol. 168 (2006) 2036-2053
30. Kato A., Kimura H., Okabe K., Okabe J., Kunou N., Nozaki M., and Ogura Y. Suppression of laser-induced choroidal neovascularization by posterior sub-tenon administration of triamcinolone acetonide. Retina 25 (2005) 503-509
31. Killingsworth M.C. Angiogenesis in early choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 233 (1995) 313-323
32. Kim Y.R., Yudina A., Figueiredo J., Reichardt W., Hu-Lowe D., Petrovsky A., Kang H.W., Torres D., Mahmood U., Weissleder R., and Bogdanov Jr. A.A. Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor. Cancer Res. 65 (2005) 9253-9260
33. Kinose F., Roscilli G., Lamartina S., Anderson K.D., Bonelli F., Spence S.G., Ciliberto G., Vogt T.F., Holder D.J., Toniatti C., and Thut C.J. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Mol. Vis. 11 (2005) 366-373
34. Krzystolik M.G., Afshari M.A., Adamis A.P., Gaudreault J., Gragoudas E.S., Michaud N.A., Li W., Connolly E., O'Neill C.A., and Miller J.W. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120 (2002) 338-346
35. Lau D., McGee L.H., Zhou S., Rendahl K.G., Manning W.C., Escobedo J.A., and Flannery J.G. Retinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2. Invest. Ophthalmol. Vis. Sci. 41 (2000) 3622-3633
36. Lebherz C., Maguire A.M., Auricchio A., Tang W., Aleman T.S., Wei Z., Grant R., Cideciyan A.V., Jacobson S.G., Wilson J.M., and Bennett J. Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. Diabetes 54 (2005) 1141-1149
37. Littell R.C., Milliken G.A., Stroup W.W., and Wolfinger R.D. SAS System for Linear Models (1996), SAS Institute, Cary, NC
38. Liu M., and Regillo C.D. A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials. Curr. Opin. Ophthalmol. 15 (2004) 221-226
39. Lopez P.F., Sippy B.D., Lambert H.M., Thach A.B., and Hinton D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 37 (1996) 855-868
40. Macular Photocoagulation Study Group. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch. Ophthalmol. 111 (1993) 1200-1209
41. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., Shalinsky D.R., Hu-Lowe D.D., and McDonald D.M. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116 (2006) 2610-2621
42. McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V., Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.C., Villafranca J.E., and Appelt K. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 7 (1999) 319-330
43. Mori K., Ando A., Gehlbach P., Nesbitt D., Takahashi K., Goldsteen D., Penn M., Chen C.T., Mori K., Melia M., Phipps S., Moffat D., Brazzell K., Liau G., Dixon K.H., and Campochiaro P.A. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am. J. Pathol. 159 (2001) 313-320
44. Motzer R.J., Hoosen S., Bello C.L., and Christensen J.G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs 15 (2006) 553-561
45. Nakahara T., Norberg S.M., Shalinsky D.R., Hu-Lowe D.D., and McDonald D.M. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 66 (2006) 1434-1445
46. Niesman M.R., Grove C.G., Rewolinski D.A., Cartwright C.A., Bender S.L., Zou H.Y., Heller D.C., Misialek S., Parast C., and Appelt K. Inhibitors of VEGF receptor-2 induce capillary regression in the retina of rats during vascular development and following exposure to cyclic hyperoxia/hypoxia. Invest. Ophthalmol. Vis. Sci. 41 (2000) S142
47. Okada A.A., Wakabayashi T., Kojima E., Asano Y., and Hida T. Trans-Tenon's retrobulbar triamcinolone infusion for small choroidal neovascularisation. Br. J. Ophthalmol. 88 (2004) 1097-1098
48. Rewolinski D.A., Grove C.G., Cobbs M.N., Goldman J.H., and Niesman M.R. A potent and selective inhibitor of VEGFR and PDGFR inhibits ocular angiogenesis. Invest. Ophthalmol. Vis. Sci. 46 (2005) 469
49. Rewolinski D.A., Jacobs S.A., Grove C.G., Cartwright C.A., Scales L.S., Goldman J.H., Zou H.Y., Cripps S.J., Kania R.S., and Niesman M.R. Analysis of angiogenic growth factors in rat retina following inhibition of VEGF-receptor 2. Invest. Ophthalmol. Vis. Sci. 42 (2001) S92
50. Rosenfeld P.J., Schwartz S.D., Blumenkranz M.S., Miller J.W., Haller J.A., Reimann J.D., Greene W.L., and Shams N. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112 6 (2005) 1048-1053
51. Saishin Y., Saishin Y., Takahashi K., Lima e Silva R., Hylton D., Rudge J.S., Wiegand S.J., and Campochiaro P.A. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. Physiol. 195 (2003) 241-248
52. Schoffski P., Dumez H., Clement P., Hoeben A., Prenen H., Wolter P., Joniau S., Roskams T., and Van Poppel H. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann. Oncol. 17 8 (2006) 1185-1196
53. Spilsbury K., Garrett K.L., Shen W.Y., Constable I.J., and Rakoczy P.E. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am. J. Pathol. 157 (2000) 135-144
54. Takeda A., Hata Y., Shiose S., Sassa Y., Honda M., Fujisawa K., Sakamoto T., and Ishibashi T. Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor. Graefes Arch. Clin. Exp. Ophthalmol. 241 (2003) 765-772
55. Tolentino M.J., Brucker A.J., Fosnot J., Ying G.S., Wu I.H., Malik G., Wan S., and Reich S.J. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24 (2004) 132-138
56. Wang F., Rendahl K., Manning W.C., Quiroz D., Coyne M., and Miller S.S. Inhibition of choroidal neovascularization (CNV) by adeno-associated virus (AAV) mediated expression of sFLT1. Invest. Ophthalmol. Vis. Sci. 43 (2002) U1307
57. Wang F., Rendahl K.G., Manning W.C., Quiroz D., Coyne M., and Miller S.S. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest. Ophthalmol. Vis. Sci. 44 (2003) 781-790
58. Wang F., Shi G., Rendahl K.G., Manning W.C., Jafari A., Liu W., Coyne M., and Miller S.S. Inhibition of choroidal neovascularization (CNV) by adeno-associated virus (AAV) mediated expression of PEDF. Invest. Ophthalmol. Vis. Sci. 44 (2003) U281
59. Wang F.E., Jafari A., Shi G., Rendahl K.G., Manning W.C., Coyne M., and Miller S.S. Changes in mRNA expression and protein level of angiogenic and anti-angiogenic factors in cultured human fetal retinal pigment epithelium (hfRPE). Invest. Ophthalmol. Vis. Sci. 45 (2004) U198